Category Archives: Psychedelics

Miami, Florida--(Newsfile Corp. - October 19, 2022) - DoseConnect, a first-of-its-kind talent company solely focused on psychedelic therapeutics. Blending organizational strategy, systems thinking, and talent acquisition grounded in conscious connection, DoseConnect is built to help companies in this space scale for hyper-growth, and will be sponsoring the Tech Stage Wonderland Miami Conference by Microdose on November 3rd, 2022.

Visit us at the Tech Stage on November 3rd, or through the conference in the Exhibitor Hall to learn more about how our team can help build companies and create conscious cultures from the ground up because we know what it takes to find and land a dream team.

"We are thrilled to launch our services in support of the psychedelic medicine industry and couldn't think of a better opportunity to do this than at Wonderland in 2022" - Dom Farnan, DoseConnect CEO

Get tickets: Use DOSECONNECT20 to save 20% on tickets. Click this link to have it automatically applied: https://tickets.microdose.buzz/attendance/event/index/41737/EN?promocodes=DOSECONNECT20

About DoseConnectDriven towards future healing and wellbeing, DoseConnect is a first-of-its-kind talent company solely focused on psychedelic therapeutics. Blending organizational strategy, systems thinking, and talent acquisition grounded in conscious connection, DoseConnect is built to help companies in this space scale for hyper-growth. Working directly with founders, visionaries and high-level operators, the team at DoseConnect helps companies with everything from human resources systems and compliance to growth culture transformation. DoseConnect is founded by Dom Farnan, CEO and Erica Downing, COO - the dynamic duo behind DotConnect, a 2021 Inc5000 company focused on talent acquisition and retention. For more information, please visit http://www.DoseConnect.io.

Erica Downing(erica@doseconnect.io)

About Wonderland by Microdose Psychedelic InsightsWonderland: Miami will offer the industry a unique in-person convergence of business, science, music, and emerging technologies. The event is a thought-leadership platform and an opportunity to connect with influential leaders in science, policy, and business. It will also act as a launching pad for innovative content connected to the psychedelic medicine space, providing compelling entertainment and collaboration opportunities for attendees.

About Microdose Psychedelics InsightsMicrodose Psychedelic Insights is your guide to the psychedelic medicine industry. With a vision to shift the world's perception of psychedelic medicine, we distribute and create the most compelling content, financial analysis, engaging events, and groundbreaking education to drive the psychedelics industry to the forefront of modern medicine.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/141126

See original here:

DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga

Todays continued rally across equity markets is providing a bullish lift to many investors who have had their sentiment beat down to a great degree this year. While broad-based, certain sectors of the market are rallying more than others today. Among the leading stocks investors are watching are psychedelic companies such asBright Minds (NASDAQ:DRUG). Todays 30% surge inDRUG stock is emblematic of some of the moves were seeing today.

As fellowInvestorPlacecontributor William White pointed out,Mind Medicine(NASDAQ:MNMD) is another big mover, surging 10% higher earlier today. This sector has gained steam from some intriguing comments made by Sen. Cory Booker from New Jersey. In a video posted on Twitter yesterday, Booker outlined his case for why psychedelics could pose therapeutic solutions and should be looked at through a scientific lens.

Bookers view is shared by many investors in psychedelic stocks. However, seeing this rhetoric displayed is something thats certainly raising eyebrows and boosting the sector today.

Lets dive into what investors should make of this news.

Psychedelic drugs such as psilocybin and MDMA have shown some pretty impressive results in International studies on therapeutic solutions for disorders such as post-traumatic stress disorder (PTSD) and depression.

That said, because of laws prohibiting the use of these drugs in the U.S., little research has been conducted stateside. Booker and others are leading the charge to shift the paradigm to a science-first approach to these drugs.

For companies like Bright Minds, a biotech focused on psychedelic therapies for such disorders, todays rhetoric is good news. Potential decriminalization or legalization efforts start with words. And right now, while were still in the very early innings of what will need to be much deeper discussions on the topic, its a start. Indeed, investors have reason to be excited about DRUG stock right now.

On the date of publication, Chris MacDonald did not have (either directly or indirectly) any positions in the securities mentioned in this article.The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines.

Chris MacDonalds love for investing led him to pursue an MBA in Finance and take on a number of management roles in corporate finance and venture capital over the past 15 years. His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Original post:

What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace

Psychedelics can produce positive changes in attitudes about death and dying and may be a way to help ease anxiety and depression toward the end of life, new research suggests.

In a retrospective study of more than 3000 participants, near-death experiences occurring naturally or via a psychedelic drug had a "remarkably" similar effect on attitudes about death and dying, with most participants reporting less fear and anxiety around death.

"Individuals with existential anxiety and depression at end of life account for substantial suffering and significantly increased health care expenses from desperate and often futile seeking of intensive and expensive medical treatments," co-investigator Roland Griffiths, PhD, Center for Psychedelics and Consciousness Research at Johns Hopkins Medicine, Baltimore, Maryland, told Medscape Medical News.

"The present findings, which show that both psychedelic and non-drug-occasioned experiences can produce positive and enduring changes in attitudes about death, suggest the importance of future prospective experimental and clinical observational studies to better understand mechanisms of such changes as well as their potential clinical utility in ameliorating suffering related to fear to death," Griffiths said.

The results were published online August 24 in PLOS ONE.

Both psychedelic drug experiences and near-death experiences can alter perspectives on death and dying, but there have been few direct comparisons of these phenomena, the investigators note.

In the current study, they directly compared psychedelic-occasioned and nondrug experiences, which altered individuals' beliefs about death.

The researchers surveyed 3192 mostly White adults from the United States, including 933 who had a natural, nondrug near-death experience and 2259 who had psychedelic near-death experiences induced with lysergic acid diethylamide, psilocybin, ayahuasca, or N,N-dimethyltryptamine.

The psychedelic group had more men than women and tended to be younger at the time of the experience than was the nondrug group.

Nearly 90% of individuals in both groups said that they were less afraid of death than they were before their experiences.

About half of both groups said they'd encountered something they might call "God" during the experience.

Three quarters of the psychedelic group and 85% of the nondrug group rated their experiences as among the top five most personally meaningful and spiritually significant events of their life.

Individuals in both groups also reported moderate- to strong-lasting positive changes in personal well-being and life purpose and meaning after their experiences.

However, there were some differences between the groups.

Compared with the psychedelic group, the nondrug group was more likely to report being unconscious, clinically dead, or that their life was in imminent danger.

The nonpsychedelic group was also more likely to report that their experience was very brief, lasting 5 minutes or less.

Both the psychedelic and nondrug participants showed robust increases on standardized measures of mystical and near-death experiences, but these measures were significantly greater in the psychedelic group.

The survey findings are in line with several recent clinical trials showing that a single treatment with the psychedelic psilocybin produced sustained decreases in anxiety and depression among patients with a life-threatening cancer diagnosis.

This includes a 2016 study by Griffiths and colleagues, which included 51 patients with late-stage cancer. As reported at the time by Medscape Medical News, results showed a single, high dose of psilocybin had rapid, clinically significant, and lasting effects on mood and anxiety.

Limitations of the current survey cited by the researchers include the use of retrospective self-report to describe changes in death attitudes and the subjective features of the experiences. Also, respondents were a self-selected study population that may not be representative of all psychedelic or near-death experiences.

In addition, the study did not attempt to document worldview and other belief changes, such as increased belief in afterlife, that might help explain why death attitudes changed.

Looking ahead, the researchers note that future studies are needed to better understand the potential clinical use of psychedelics in ameliorating suffering related to fear of death.

Support through the Johns Hopkins Center for Psychedelic and Consciousness Research was provided by Tim Ferriss, Matt Mullenweg, Blake Mycoskie, Craig Nerenberg, and the Steven and Alexandra Cohen Foundation. Funding was also provided by the Y.C. Ho/Helen and Michael Chiang Foundation. The investigators have reported no relevant financial relationships.

PLOS ONE. Published online August 24, 2022. Full article

For more Medscape Psychiatry news, join us on Twitter and Facebook

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

View post:

Psychedelics May Ease Fear of Death and Dying

The Drug Enforcement Administration (DEA) is proposing a significantincrease in the amount of researchcannabis allowed to becultivatedin 2023. According to anoticescheduled to be published in the Federal Register on Tuesday, the agency is also looking to boost the aggregate production quota of certain psychedelics likeLSD, psilocin, and mescaline,firstreportedMarijuana Moment.

For 2023,the DEA is proposingthat 6.7 million grams (14,770 pounds) of marijuana be grown for research, more than double the amount suggested for 2022 (3.2 million grams). In January this year, the DEAended a 5-decade federal monopolyon research cannabis production byapproving two companies, Groff North America Hemplex and Biopharmaceutical Research Company (BRC), to cultivate marijuana for research purposes.

This was a major milestone in the cannabis research sphere in that afarm functioning as part of theUniversity of Mississippiwasthe only legal source of federal research cannabissince 1968, despitelawsuitsand years of complaints that Ole Miss's product was not high enough quality to suffice for important research.

With more cultivators gaining DEAauthorization for cultivation, increasing the amount needed for research is achievable.

Whats more, the DEA also raised the quota for all other THC to 15,000 grams from previously 2,000 grams, indicating the popularity and therefore the need for research into cannabinoids likedelta-8 THC, and delta-10.

The agency has been raising production quotas for psychedelics over the last couple of years. For example, last December itincreased its quotafor psilocybin (also known as magic mushrooms), MDMAand DMT for 2022. This move came amid an increase in demand and interest within the scientific community to research the effectiveness of these psychedelic drugs in treatments for mental health disorders.

This time, the DEA proposed to keep the same quote for psilocybin as in 2022,8,000 grams, but it is suggesting to double the production of other important components of magic mushrooms, such aspsilocin from 4,000 to 8,000 grams. As forLSD,the proposed quota for 2023 is 1,200 grams, compared to 500 grams in 2022. The agency also suggested the production of 6,000 grams of5-MeO-DMT,compared to 2,550 grams this year.

Mescalinemanufacturing should go up notablyfrom 100 to 1,200 grams.

There has been a significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes.DEA has received and subsequently approved new registration applications for schedule I researchers and new applications for registration from manufacturers to grow, synthesize, extract, and prepare dosage forms containing specific schedule I hallucinogenic substances for clinical trial purposes,the agency stated.

These proposed 2023 quotas reflect the quantities that DEA believes are necessary to meet the estimated medical, scientific, research, and industrial needs of the United States, including any increase in demand for certain controlled substances used to treat patients with COVID-19; lawful export requirements; and the establishment and maintenance of reserve stocks.

At the same time, the DEA proposed keeping the same quotas as this year for psilocybin, MDMA, DMT, MDAand cannabis extract.

Photo: Rob Warner on Unsplash and Mathew Schwartz on Unsplash

Read the original here:

DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga

Welcome to TDRs review of the Top 5 Psychedelic Developments for the week of October 10. Aside from presenting a synopsis of events, we provide market commentary to summarize the week that was for publicly-listed companies.

5. Atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

Atai Life Sciences N.V. (Nasdaq: ATAI) announced positive initial results for their Phase 1 clinical trial of KUR-101. KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD).

Initial results indicate that KUR-101 is safe and generally well-tolerated. Results also showed a dose-proportional pharmacokinetic (PK) profile that was unaffected by food. In the single ascending oral dose portion of the trial, no severe or serious adverse events were reported, with most treatment-related adverse events being mild. Changes in respiratory rate following treatment with KUR-101 were comparable to that of placebo-treated patients for the doses tested and comparable across doses.

4. Palo Santo Closes $50M Psychedelic Therapeutics Investment Fund

Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recentlyannounced the closing of its $50 million fund.

The oversubscribed fund is positioned to have a transformative impact on the field ofmental health by funding a diverse portfolio of businesses developing innovative psychedelic medicines and therapiestargeting both mental health as well as a range of Central nervous system(CNS) disorders.

The Palo Santo Fundiscurrently investedin over 20 portfolio companies across the psychedelic ecosystem. Moreover, the company combines its investing and portfolio-building experience with the expertise of leading academics and advisors in psychedelic science.

__________

DEA Proposes Dramatic Increases In Cannabis And Psychedelics Production In 2023 For Research

__________

3. Psychedelic Sector Dives As Bears Maintain Control

The psychedelic sector dove this past week, as reflected by theHorizon Psychedelic Stock Index (PSYK) ETF(14.67%). The ETF vastly underperformed theNasdaq Junior Biotechnology Index(2.16%) andNasdaq Biotechnology Ishares ETF(0.62%), which both trending inline or better with the the broad indices. TheNASDAQ 1003.16%andS&P 5001.53% fell, where higher-than-consensus Consumer Price Index readings implied additional & robust rate hikes ahead.

Heres how the Health Care (Biotechnology) sector performed:

In the news

Algernon Pharmaceuticals announced that Dr. Rick Strassman, author of the bookDMT: The Spirit Moleculeand Algernon consultant, will be joining CEO Christopher J. Moreau for the Science Keynote Address at Wonderland, the world-leading event in the psychedelic medicine industry.

American Psychedelic Practitioners Association has announced the launch of their organization, establishing safe, ethical and accessible psychedelic therapy and specific focus Psychedelic Assisted Therapy.

Clerkenwell Health, a psychedelic-specialist clinical research organization, has raised 2.1 million in seed funding, bringing the total to date up to 2.5 million, which will be used to get the London-based startup fully operational.

Coloradovoters will decide this November whether to decriminalize the possession and use of some hallucinogenic plants and fungi, including magic mushrooms.

Cybin Inc. and The Chopra Foundation, a not-for-profit organization dedicated to improving health and well-being founded by Dr. Deepak Chopra, join everyone in recognizing World Mental Health Day.

Drug Enforcement Agency is proposing to more than double the amount of marijuana that can be legally grown for research in 2023 and is also increasing quotas for psychedelics like psilocyn, LSD and 5-MeO-DMTwith a 12x bump for mescaline.

Field Trip Health & Wellness announced that a new version of its award-winning app for psychedelic guidance is now available for download on the App Store and Google Play.

Giving lab rats illicit psychedelic drugs may help scientists uncover how it can be used to treat anorexia in humans.

IntelGenx Corp. provided an update on its collaboration with its strategic partner, atai Life Sciences, for the development of novel formulations of pharmaceutical-grade psychedelics based on IntelGenxs polymeric film technologies.

Kratomgrows in severalAsian countriesand has been traditionally used by local communities as anatural home remedy for pain, depression and addiction. Now, several psychedelics companies are developingsubstancesbased on this plant and severalUS stateshave alreadyenactedlegislationthat regulates its production, distribution and sale.

Lobe Sciences has completed the synthesis of bulk L-130, a proprietary form of psilocin, and of the clinical supplies to be used in upcoming trials. The L-130 was manufactured in compliance with U.S. cGMPs (Current Good Manufacturing Practices).

LOVE Pharma provided an update on the advancement of the previously announced trial focused upon clinical applications for psilocybin assisted therapy for addiction to be conducted at Johns Hopkins.

Optimi Health has closed a non-brokered private placement of 5,692,308 units of the company at a price of $0.325 per Unit for gross proceeds of $1,850,000 with Wilson Capital, the Private Equity Division Chip Wilsons family office.

PsyBio Therapeutics has reached an initial agreement with experienced clinical researchers to conduct a clinical trial utilizing PsyBios proprietary biosynthetic psilocybin product upon obtaining all necessary approvals and licenses.

Psychedelic rock band Jefferson Airplane was awarded a star on the Hollywood Walk of Fame.

Red Light Holland announced that Red Light Holland Advisory Board member, Akwasi Owusu-Bempah will participate at Bloomberg CityLab 2022, being held in Amsterdam, The Netherlands, October 9-11, 2022.

Relmada Therapeutics said its therapy to treat major depressive disorder did not meet the main goal of a late-stage study.

Revitalist Lifestyle & Wellness has extinguished its contract with High Standard Capital by issuing 1,282,051 common shares at $0.078 per share. These shares are subject to the Companys filing requirements with the CSE and a hold period of four months and a day from the date of issuance.

Voters in five states will decide on marijuana legalization on their November ballotsand voters in one state will have the chance to enact a historic reform to legalize psychedelics possession.

2. Elon Musk reportedly goes on exploratory journeys, likes to show chart of benefits of MDMA, mushrooms

Elon Musk is no stranger to psychedelic drugs and often likes to discuss the benefits of the substances, according to arecent report from The New York Times.

The billionaire likes to share a chart that shows MDMA and psychedelic mushrooms are healthier than alcohol use, one person who Musk shared the chart with on vacation told the publication.

The Times spoke with over 40 people who have spent time with the richest man in the world over the past decade and a half, many under conditions of anonymity due to concerns of repercussions, as well as non-disclosure agreements that they were required to sign at the parties Musk attended.

1. COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

COMPASS Pathways plc (Nasdaq: CMPS) announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in treatment resistant depression (TRD) during a virtual Capital Markets Day. COMPASS program will be the first ever Phase 3 program of psilocybin therapy globally, and follows positive results from its Phase 2b study in treatment-resistant depression,presented at the American Psychiatric Association annual meeting in May 2022.

The Phase 3 program is composed of three clinical trials, two pivotal trials and one long-term follow-up, and is expected to commence by the end of 2022. The pivotal program design is as follows:

Original post:

TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report

AN NHS DOCTOR is set to deliver a talk discussing the possibility of using psychedelics to tackle mental health conditions.

Dr Jonathan Iliff will speak about the history and future of the practice at the University of Reading on Thursday, October 27.

A background into how psychedelics produce their effects in the brain will be provided, also touching on how people might benefit from consuming compounds such as psilocybin and LSD.

His research focused on the use of psychedelic compounds, like LSD and psilocybin, the active ingredient in magic mushrooms, in the treatment of mental health disorders.

He has expressed his desire to remove the stigma from speaking about mental health and change attitudes which persist in even the most tolerant parts of our society.

The founder of the UCL Society for the Application of Psychedelics hopes to improve the lives of billions of people who suffer directly and indirectly from mental health disorders.

The event is part of the Seed Talks series, which connects top thinkers with audiences across the UK.

Its stapline is: Learn something new. Plant an idea. Watch it grow.

This talk takes place at the Palmer G.10 Lecture Theatre, Pepper Lane.

Doors open at 6.45pm, with the event running from 7.30pm-9.30pm.

There are various ticket options available, starting from 10.90.

For more information or to book tickets, search Seed Talks on http://www.eventbrite.co.uk

Link:

Talk set to explore psychedelics and mental health - Reading Today

Springfield, Oregon--(Newsfile Corp. - October 17, 2022) - Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("Silo Wellness" or the "Company"), Oregon's only publicly traded psychedelics company, is pleased to announce it has closed its acquisition of 100% of Dyscovry Science Ltd. ("Dyscovry"), a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition, irritable bowel syndrome.

"Bringing the Dyscovry team into the Silo Wellness family is a key component to our pharmaceutical vision which began with our July 2019 priority date for our patent-pending metered-dosing modalities for psilocybin, mescaline, DMT, and 5-MeO-DMT," stated Silo Wellness founder and CEO Mike Arnold, an Oregon attorney. "With our presence and founding in Oregon along with our psychedelic retreat operational experience in Jamaica [with psilocybin and 5-MeO-DMT] and Oregon [with ketamine], Dyscovry's portfolio will allow us to further our goal of covering both tracks of the psychedelic industry under one roof: psychedelic healing now via jurisdiction-by-jurisdiction "adult use" and pharmaceutical biotech."

Terms of the transaction, which was an arm's length acquisition with no finder's fees paid, can be found in the Company's September 27, 2022 press release announcing the signing of the September 26, 2022, definitive agreement. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.

ABOUT DYSCOVRY

DYSCOVRY SCIENCE LTD is an innovative Toronto-based biotechnology company conducting research to establish a world-leading position in the development of fungal- and plant-derived therapeutics through its proven drug discovery and development processes, its growing intellectual property portfolio, and regulatory and manufacturing expertise.

Story continues

Dyscovry is led by an experienced team with government, university and private collaborations focusing on biosynthesis of psilocybin and investigating a quantifiable anti-inflammatory effect of psychedelics - believed to be mediated through 5-HT2A activation - and how this relationship pertains to disorders that affect the large intestine. Dyscovry is focused on indications such as Irritable Bowel Syndrome (IBS) that inflict suffering on a double digit percentage of the entire human global population. This suffering includes the physiological symptoms but also the secondary psychological symptoms from living with this disease.

http://www.Dyscovry.com

ABOUT SILO WELLNESS

Silo Wellness is a growth-oriented holding company focused on psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 in Oregon and headquartered in Toronto, Silo Wellness has a presence in both Jamaica and Oregon. Silo Wellness is a publicly traded company on the Canadian (CSE: SILO) and Frankfurt (FSE: 3K7A) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF).

For more information about Silo Wellness or to book a Jamaican psychedelic retreat, please visit http://www.silowellness.com.

Silo Wellness Company Contact:

Mike Arnold, President541-900-5871IR at silo wellness dot com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking information may relate to anticipated events or results including, but not limited to Dyscovry's development of certain technologies and products; Dyscovry's initiation of research, clinical trials and timing thereof; Dyscovry's successful completion of clinical trials; the Company's ability to fund Dyscovry's as well as the company's pre-existing capital requirements; and any potential success in perfecting any patent claims. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, regulatory, political and social uncertainties and the potential impact of COVID-19. Such risks and uncertainties include, among others, the risk factors included in Silo Wellness's continuous disclosure documents available on http://www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/140629

See the rest here:

Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance

Psilocybin, a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi, rewires the brain in depressed people and has the potential to cure them of their depression, study finds.

Psilocybin, the compound found in magic mushrooms, improves connections between different regions of the brain in depressed people.

This allows the individual to escape excessive rumination and self-focus, says a study by scientists at UC San Francisco and Imperial College London.

60 people participated in two psilocybin trials and had their fMRI brain scans analysed by scientists.

In the first psilocybin trial, all the participants were considered to have treatment-resistant depression and were aware that they were being given psilocybin.

In comparison, the participants in the second trial were depressed but not as severely. They were also not told whether they had been given psilocybin or a placebo that turned out to be escitalopram, an SSRI antidepressant. In addition to the substances, all the participants received the same type of psychotherapy.

Scans were taken before and after treatment. The results showed that the psilocybin treatment reduced connections within brain areas that are tightly connected in depression.

This included:

Moreover, study volunteers were also less emotionally avoidant and found that their cognitive functioning improved drastically.

According to this research, scientists found that psilocybin rewires the brain for up to three weeks after the second psilocybin dose.

In the individuals who received escitalopram, there were no such changes. This strongly suggests that psilocybin acts differently on the brain.

Psilocybin and other serotonergic psychedelics like ayahuasca affect 5-HT2A receptors, which are plentiful in brain networks that become overactive in depression.

One hypothesis is that the drugs briefly disrupt these connections, giving them a chance to reform in new ways in the ensuing days and weeks.

In previous studies we had seen a similar effect in the brain when people were scanned whilst on a psychedelic, but here were seeing it weeks after treatment for depression, which suggests a carry-over of the acute drug action, commented Robin Carhart-Harris, PhD, who directs the Neuroscape Psychedelics Division at UCSF and is the senior author of the study, which appears in Nature Medicine.

We dont yet know how long the changes in brain activity seen with psilocybin therapy last

We dont yet know how long the changes in brain activity seen with psilocybin therapy last, and we need to do more research to understand this, said Carhart-Harris, who is the Ralph Metzner Distinguished Professor of Neurology, Psychiatry, and Behavioral Sciences and a member of the UCSF Weill Institute for Neurosciences.

We do know that some people relapse, and it may be that after a while their brains revert to the rigid patterns of activity we see in depression.

The authors add that whilst they feel very encouraged by these findings, they warn that patients with depression should not attempt to self-medicate with psilocybin.

The trials took place under controlled, clinical conditions, using a regulated dose formulated in a laboratory, and involved extensive psychological support before, during, and after dosing.

Psilocybin rewires the brain in such a way that it may help alleviate depression and other debilitating psychiatric conditions. And it is not the only type of psychedelic effective against mental health issues and psychiatric conditions that are marked by fixed patterns of thinking.

For the first time we find that psilocybin works differently from conventional antidepressants making the brain more flexible and fluid, and less entrenched in the negative thinking patterns associated with depression, concluded David Nutt, DM, head of the Imperial Centre for Psychedelic Research.

This supports our initial predictions and confirms psilocybin could be a real alternative approach to depression treatments.

Editor's Recommended Articles

Continue reading here:

How does psilocybin rewire the brain? - Open Access Government

HYTN Innovations Inc.

VANCOUVER, British Columbia, Oct. 17, 2022 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (HYTN or the Company) (CSE: HYTN), a leading cannabis company focused on creating consistent, natural and delicious cannabis products, is pleased to announce that its wholly owned subsidiary, HYTN Cannabis Inc., has been awarded a Controlled Drugs and Substances Dealers Licence (the License) by Health Canada allowing for the sale, possession, production, assembly and transportation of psilocybin, a naturally occurringpsychedelicprodrugcompound produced by a number of fungi.

This announcement follows several license achievements including a Standard Processing License and its Amendment for Sale, a Cannabis Research License, a Standard Cultivation License, and a Medical Sales License (with possession). The Company notes that this achievement has not been widely accomplished by Canadian cannabis licence holders and demonstrates the Companys ability to work with regulators to enhance licenced activities within its purpose-built ISO 9001:2015 accredited Kelowna production facility.

This is a considerable achievement, said Elliot McKerr, HYTN Chief Executive Officer. The emerging regulated psychedelics market is taking form and we have seen considerable interest from researchers, physicians, and potential pharmaceutical partners in obtaining products containing psilocybin. We believe this license, combined with the intellectual property that HYTN possesses in formulating and manufacturing cannabis products, ensures HYTN is well-positioned for future growth driven by increasing access to psilocybin in Canada and around the world. Anticipating the evolving landscape of controlled substance access is paramount to ensuring HYTN is at the forefront of product development and future revenue opportunities.

HYTN Chief Operating Officer, Jason Broome, adds, This license further demonstrates HYTNs sophisticated operational capacity and the strength of our well scaled multi-purpose facility and quality systems. We are now able to begin formulating and testing products containing psilocybin. This work will provide a strong foundational competitive advantage, ensuring HYTN is well positioned to service the current clinical trial market and future medical and recreational markets should they open.

Story continues

Under the License, the Company may possess up to 300 grams of psilocybin or its equivalent in biomass at any time and can sell or transfer extracted material or final drug products to other licenced dealers or authorized markets outside of Canada. HYTN intends to begin researching and developing psilocybin-based products that complement its current offerings of cannabis beverages and edibles.

About HYTN Innovations Inc.

HYTN formulates, manufactures, markets, and sells premium cannabis goods. With the mission to be the leading provider of consistent, natural, and delicious cannabis products, HYTN focuses its efforts on identifying category opportunities and takes an innovative approach to delivering elevated cannabis experiences to a discerning customer base.

Please visit http://www.hytn.life for more information or contact:

Elliot McKerrChief Executive Officer1.866.590.9289

HYTN Investor Relations1.866.590.9289investments@hytn.life

The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.

Certain information contained herein may constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including, but not limited to, statements regarding: (i) expected developments in the emerging regulated psychedelics market; (ii) expected benefits of the License; and (iii) HYTNs intention to begin researching and developing psilocybin-based products that complement its current offerings of cannabis beverages and edibles. Factors that could cause actual results to vary from forward-looking statements or may affect the operations, performance, development and results of the Companys business include, among other things: the Companys ability to generate sufficient cash flow from operations to meet its current and future obligations; the Companys ability to access sources of debt and equity capital; competitive factors, pricing pressures and supply and demand in the Companys industry; general economic and business conditions; and the effects and impacts of the COVID-19 pandemic, the extent and duration of which are uncertain at this time, on the Companys business and general economic and business conditions and markets. Any statements that are not statements of historical fact are deemed to be forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether as a result of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note.

See the rest here:

HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance

Your Super ranked #1 in the food and beverage category on Inc.'s 2021 5000 fastest growing company list, placing 25th overall with three-year revenue growth of 11,477 percent and $180M in cumulative revenue

The Healing Company and Your Super will partner to capitalize on two high-growth wellness sectorssuperfoods and plant-based nutrition

Acquisition financed through a combination of cash and equity in The Healing Company. Previous investors in Your Super include PepsiCo and Beyond Meat investor, PowerPlant Partners

$150M credit facility from i80 Group will fuel further acquisitions

The Healing Company is co-founded by former IMG Model and supplements entrepreneur Anabel Oelmann, and exJet.com and Equinox Media President Simon Belsham

Investors and advisors of The Healing Company include global wellbeing icon Dr. Deepak Chopra, MD, renowned investor and psychedelics entrepreneur Christian Angermayer, and Social Chain & Thirdweb founder and Dragons Den member Steven Bartlett

NEW YORK, Oct. 17, 2022 /PRNewswire/ -- (OTC: HLCO)- The Healing Companyhas achieved a major milestone in its mission to bring integrated healing to the world, acquiring leading plant-based superfoods brand, Your Super. In parallel with the closing of the transaction, The Healing Company also announced the closing of a $150 million credit facility provided by i80 Group.

With previous fundraising from PepsiCo and Beyond Meat investor, PowerPlant Partners, Your Super has demonstrated the ability to grow quickly, while maintaining strong margins and a positive EBITDA outlook. The company has sold more than 5M products across the US and Europe, ranking 25th on the 2021 Inc. fastest growing companies list with three-year revenue growth of 11,477 percent and $180M in cumulative revenue, and is focused on two high-growth wellness sectors, superfoods and plant-based nutrition, representing more than $200bn of global market potential.The acquisition was financed through a combination of cash and HLCO equity, and will focus on expanding the impact and accessibility of Your Super's leading portfolio of healing products, building on the company's traction to date.

Story continues

The wellness industry is predicted to reach $7 trillion by 2025, with the supplement category historically showing stability in a downturn, growing 8% through the 2007-2009 recession. The new credit facility provided by i80 Group will fuel The Healing Company's plans to drive consolidation in a fragmented market, with the objective of buying and scaling more than 15 supplements and nutraceuticals brands over the next few years. The market is favorable for M&A, with valuations dropping considerably from 2021, creating substantial tailwinds for The Healing Company's roll-up strategy.

Co-founded by former IMG Model and supplements entrepreneur Anabel Oelmann, and ex Jet.com and Equinox Media President Simon Belsham, The Healing Company launched earlier this year. It is backed by a group of disruptors, entrepreneurs, and healers including world-renowned pioneer in integrative medicine and personal transformation Dr. Deepak Chopra, eminent investor and psychedelics entrepreneur Christian Angermayer, and Social Chain and Thirdweb founder and Dragons Den member Steven Bartlett.

Simon Belsham, Co-Founder and CEO of The Healing Company, says: "Your Super is the perfect first acquisition for The Healing Company. With great founders, a powerful brand, robust margins, and a fantastic product portfolio in a large and growing sector, Your Super couldn't be better positioned to succeed in this challenging economy. With 100 million Americans in medical debt and facing a likely recession, preventative healthcare has never been more relevant or important. I couldn't be more excited to partner with Kristel and Michael on this next phase of growth."

Michael Kuech, Co-Founder of Your Super, says "We are thrilled to enter this new chapter alongside The Healing Company and look forward to growing the healing impact of Your Super with the guidance of such a pioneering team; there couldn't be a better partner to take us to the next level."

Dr. Deepak Chopra, MD, Chief Scientific Advisor of The Healing Company, says "Food is medicine, and we now know definitively that plant-based nutrition has immense healing potential as it combats inflammation, which causes more than 80% of chronic disease. Your Super has developed clean, plant-based, superfood mixes that help more people benefit from the healing power of plants, and we're excited to help increase access to their products through this acquisition."

Marc Helwani, Founder and CIO of i80 Group,says,"The Healing Company's targeted acquisition strategy is highly attractive in the currently challenged economic environment as we've seen declining asset prices this year, and we expect them to fall further. The Healing Company's experienced and visionary team is perfectly positioned to capitalize on this, and we're proud to partner with them on this venture."

Anabel Oelmann, Co-Founder of The Healing Company, adds: "Over the past 6 months we've met with hundreds of businesses and inspirational founders. Our strong mission alignment, immense conviction in the opportunity to scale this business and tremendous founders in Kristel and Michael, make us proud to have Your Super as our marquee first acquisition"

All press imagery can be found here, with a link to the launch video available here.

About The Healing Company

The Healing Company Inc. was founded with a bold aim: Bring integrated healing to the world. Compelled by the global healthcare crisis and a deep belief in a different wayone which draws on conventional medicine and ancient wisdom, science and naturethe company looks to democratize access to integrated healing methods, while helping the world evolve how it thinks about health and healthcare.

To do so, the company is building a community of integrated healing brands, identifying, acquiring, and helping scale the reach and impact of healing practices & products.

The Healing Company's common stock is quoted for trading on the OTC Markets under the ticker symbol HLCO, and its investors and advisors include global wellbeing icon Dr. Deepak Chopra, MD, renowned investor and psychedelics entrepreneur Christian Angermayer, and Social Chain & Thirdweb founder and Dragons Den member Steven Bartlett. For more information, visit http://www.healingcompany.com.

About Your Super

Los Angeles-based health and wellness brand and certified B-Corp Your Super is a next-gen industry leader in plant-based living. After Co-Founder Michael Kuech was diagnosed with cancer at age 24, his Co-Founder and partner Kristel de Groot began developing superfood and plant protein mixes to boost his immunity, and the company was born out of the couple's mission to improve people's health with the power of super plants. Your Super's plant-based superfood and protein mixes contain 5-6 naturally dried superfoods. Every ingredient is grown, harvested, 3rd party tested, and packaged 100% sustainably. The ingredients are certified organic, Non-GMO certified, Glyphosate-Free, plant-based and gluten-free. You'll never find any sweeteners, stevia, artificial flavors, fillers, preservatives or additives.

About i80 Group

i80 Group is an investment firm designed to propel the innovation economy forward by empowering growth. The firm provides bespoke financing solutions that are unique to each partner's needs, advancing them through critical growth milestones. Like the I-80 freeway from which it takes its name, the firm operates at the intersection of Silicon Valley innovation and traditional Wall Street finance. For more information, please visit http://www.i80group.com.

Forward-looking statements:

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financial requirements, business strategy, products and services, potential future financings, acquisition and scaling of future brands and or project and its anticipated financing plans, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements; foreign exchange and other financial markets; changes in the interest rates on borrowings; hedging activities; changes costs of goods; changes in the investments and expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which The Healing Company operates. There can be no assurance that The Healing Company will achieve the above stated brand acquisitions and scaling of those brands or the closing of financing stated herein. The reader should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by The Healing Company from time to time with the Securities and Exchange Commission.

Sources:

Statista; Imarc, May 20, 2022, "Value of the superfoods market worldwide from 2021 to 2027"

Meticulous Market Research Pvt. Ltd., June 2022, "Plant-based Food Market by Type, Source, Distribution Channel - Global Forecast to 2029"

Grandview Research (2022), "Dietary Supplements Market Size, Share & Trends Analysis Report By Ingredient (Vitamins, Minerals), By Form, By Application, By End User, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030"

PwC, 2002, Global M&A Industry Trends: 2022 Mid-Year Update

New York Times, Williams, April 2009, "As Economy Is Down, Vitamin Sales Are Up"

Photo -https://mma.prnewswire.com/media/1921603/The_Healing_Company_and_Your_Super_Co_founders.jpgVideo - https://mma.prnewswire.com/media/1921602/The_Healing_Company_Acquires_Your_Super.mp4Logo -https://mma.prnewswire.com/media/1921604/The_Healing_Company_Logo.jpg

The Healing Company Co-founders, Simon Belsham and Anabel Oelmann and Your Super Co-founders, Michael Kuech and Kristel De Groot

The Healing Company Logo

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-healing-company-acquires-leading-superfoods-business-your-super-and-lands-150m-credit-facility-to-expand-community-of-brands-301650739.html

SOURCE The Healing Company

More:

The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance